Role of biomarkers in understanding and treating children with asthma: Towards personalized care

Pharmacogenomics and Personalized Medicine

Volumn 6, Issue 1, 2013, Pages 73-84

  Lang, Jason E ^a   Blake, Kathryn V ^b  

^a NEMOURS CHILDREN S HOSPITAL   (United States)

^b NEMOURS CHILDREN S CLINIC   (United States)

Author keywords

Asthma; Biomarkers; Children; Management

Indexed keywords

ANTIASTHMATIC AGENT; ARACHIDONATE 5 LIPOXYGENASE INHIBITOR; BIOLOGICAL MARKER; CORTICOSTEROID; IMMUNOGLOBULIN E; LEUKOTRIENE MODIFIER; LIPOXYGENASE INHIBITOR; MONTELUKAST; NITRIC OXIDE; PEPTIDOLEUKOTRIENE; SALBUTAMOL; TOBACCO SMOKE; UNCLASSIFIED DRUG; ZAFIRLUKAST; ZILEUTON;

ALLERGIC AIRWAY INFLAMMATION; ASPIRIN EXACERBATED RESPIRATORY DISEASE; ASTHMA; BREATH ANALYSIS; CHILD; CLINICAL TRIAL (TOPIC); DISEASE SEVERITY; DRUG METABOLISM; DRUG RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FORCED EXPIRATORY VOLUME; FRACTION OF EXPIRED NITRIC OXIDE; GENETIC ASSOCIATION; GENETIC MARKER; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE PHENOTYPE CORRELATION; HEALTH EDUCATION; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; PASSIVE SMOKING; PERSONALIZED MEDICINE; PHARMACOGENOMICS; PREVENTIVE MEDICINE; PROTEIN URINE LEVEL; RECURRENT DISEASE; RESPIRATORY TRACT PARAMETERS; REVIEW; SENSITIVITY AND SPECIFICITY; SIGNAL TRANSDUCTION; SYMPTOM;

EID: 84882744413     PISSN: None     EISSN: 11787066     Source Type: Journal    
DOI: 10.2147/PGPM.S30626     Document Type: Review

References (143)

1. Masoli M, Fabian D, Holt S, et al. The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy. 2004;59:469-478.
2. Akinbami LJ, Moorman JE, Garbe PL, et al. Status of childhood asthma in the United States, 1980-2007. Pediatrics. 2009;123 Suppl 3: S131-S145.
3. Daniels SE, Bhattacharrya S, James A, et al. A genome-wide search for quantitative trait loci underlying asthma. Nature. 1996;383:247-250.
4. Vercelli D. Discovering susceptibility genes for asthma and allergy. Nat Rev Immunol. 2008;8:169-182.
5. Caliskan M, Bochkov YA, Kreiner-Moller E, et al. Rhinovirus wheezing illness and genetic risk of childhood-onset asthma. N Engl J Med. 2013;368:1398-1407.
6. Bouzigon E, Corda E, Aschard H, et al. Effect of 17q21 variants and smoking exposure in early-onset asthma. N Engl J Med. 2008;359: 1985-1994.
7. Jackson DJ, Sykes A, Mallia P, et al. Asthma exacerbations: origin, effect, and prevention. J Allergy Clin Immunol. 2009;128:1165-1174.
8. Ito Y, Adachi Y, Itazawa T, et al. Comparison of exhalation time methods (6 sec vs 10 sec) of a hand-held exhaled nitric oxide analyzer. Pediatr Pulmonol. 2010;45:1005-1008.
9. Kalliola S, Malmberg P, Rito T, et al. Can we use portable nitric oxide analyzer in young children? Pediatr Pulmonol. 2011;46:627-631.
10. Riccioni G, Bucciarelli V, Verini M, et al. ADMA, SDMA, L-Arginine and nitric oxide in allergic pediatric bronchial asthma. J Biol Regul Homeost Agents. 2012;26:561-566.
11. Ishizuka T, Matsuzaki S, Aoki H, et al. Prevalence of asthma symptoms based on the European Community Respiratory Health Survey questionnaire and FENO in university students: gender differences in symptoms and FENO. Allergy Asthma Clin Immunol. 2011; 7:15.
12. Silvestri M, Pistorio A, Battistini E, et al. IgE in childhood asthma: relevance of demographic characteristics and polysensitisation. Arch Dis Child. 2010;95:979-984.
13. Vahlkvist S, Sinding M, Skamstrup K, et al. Daily home measurements of exhaled nitric oxide in asthmatic children during natural birch pollen exposure. J Allergy Clin Immunol. 2006;117:1272-1276.
14. Delfino RJ, Staimer N, Gillen D, et al. Personal and ambient air pollution is associated with increased exhaled nitric oxide in children with asthma. Environ Health Perspect. 2006;114:1736-1743.
15. Oguzulgen IK, Turktas H, Erbas D. Airway inflammation in premenstrual asthma. J Asthma. 2002;39:517-522.
16. Schleich FN, Seidel L, Sele J, et al. Exhaled nitric oxide thresholds associated with a sputum eosinophil count/= 3% in a cohort of unselected patients with asthma. Thorax. 2010;65:1039-1044.
17. Mahut B, Peyrard S, Delclaux C. Exhaled nitric oxide and clinical phenotypes of childhood asthma. Respir Res. 2011;12:65.
18. van der Valk RJ, Caudri D, Savenije O, et al. Childhood wheezing phenotypes and FeNO in atopic children at age 8. Clin Exp Allergy. 2012;42:1329-1336.
19. Linn WS, Rappaport EB, Berhane KT, et al. Exhaled nitric oxide in a population-based study of southern California schoolchildren. Respir Res. 2009;10:28.
20. Pijnenburg MW, Floor SE, Hop WC, et al. Daily ambulatory exhaled nitric oxide measurements in asthma. Pediatr Allergy Immunol. 2006;17:189-193.
21. Salam MT, Byun HM, Lurmann F, et al. Genetic and epigenetic variations in inducible nitric oxide synthase promoter, particulate pollution, and exhaled nitric oxide levels in children. J Allergy Clin Immunol. 2011;129:232-239 e231-e237.
22. Bessa V, Tseliou E, Bakakos P, et al. Noninvasive evaluation of airway inflammation in asthmatic patients who smoke: implications for application in clinical practice. Ann Allergy Asthma Immunol. 2008;101:226-232; quiz 232-224, 278.
23. Perzanowski MS, Divjan A, Mellins RB, et al. Exhaled NO among inner-city children in New York City. J Asthma. 2010;47:1015-1021.
24. Krishnan S, Dozor AJ. Relationship between exhaled nitric oxide and exposure to low-level environmental tobacco smoke in children with asthma on inhaled corticosteroids. J Asthma. 49:673-678.
25. Turktas H, Oguzulgen K, Kokturk N, et al. Correlation of exhaled nitric oxide levels and airway inflammation markers in stable asthmatic patients. J Asthma. 2003;40:425-430.
26. Jackson DJ, Virnig CM, Gangnon RE, et al. Fractional exhaled nitric oxide measurements are most closely associated with allergic sensitization in school-age children. J Allergy Clin Immunol. 2009;124: 949-953.
27. Buchvald F, Eiberg H, Bisgaard H. Heterogeneity of FeNO response to inhaled steroid in asthmatic children. Clin Exp Allergy. 2003;33: 1735-1740.
28. Hewitt RS, Modrich CM, Cowan JO, et al. Outcomes using exhaled nitric oxide measurements as an adjunct to primary care asthma management. Prim Care Respir J. 2009;18:320-327.
29. Jartti T, Wendelin-Saarenhovi M, Heinonen I, et al. Childhood asthma management guided by repeated FeNO measurements: a meta-analysis. Paediatr Respir Rev. 2012;13:178-183.
30. Petsky HL, Cates CJ, Lasserson TJ, et al. A systematic review and meta-analysis: tailoring asthma treatment on eosinophilic markers (exhaled nitric oxide or sputum eosinophils). Thorax. 2012;67:199-208.
31. Stern G, de Jongste J, van der Valk R, et al. Fluctuation phenotyping based on daily fraction of exhaled nitric oxide values in asthmatic children. J Allergy Clin Immunol. 2011;128:293-300.
32. Debley JS, Cochrane ES, Redding GJ, et al. Lung function and biomarkers of airway inflammation during and after hospitalization for acute exacerbations of childhood asthma associated with viral respiratory symptoms. Ann Allergy Asthma Immunol. 2012;109:114-120.
33. Singer F, Luchsinger I, Inci D, et al. Exhaled nitric oxide in symptomatic children at preschool age predicts later asthma. Allergy. 2013;68: 531-538.
34. Klaassen EM, van de Kant KD, Jobsis Q, et al. Symptoms, but not a biomarker response to inhaled corticosteroids, predict asthma in preschool children with recurrent wheeze. Mediators Inflamm. 2012;2012: 162571.
35. Arora R, Thornblade CE, Dauby PA, et al. Exhaled nitric oxide levels in military recruits with new onset asthma. Allergy Asthma Proc. 2006;27:493-498.
36. Szefler SJ, Wenzel S, Brown R, et al. Asthma outcomes: biomarkers. J Allergy Clin Immunol. 2012;129:S9-S23.
37. Burrows B, Martinez FD, Cline MG, et al. The relationship between parental and children's serum IgE and asthma. Am J Respir Crit Care Med. 1995;152:1497-1500.
38. Sherrill DL, Lebowitz MD, Halonen M, et al. Longitudinal evaluation of the association between pulmonary function and total serum IgE. Am J Respir Crit Care Med. 1995;152:98-102.
39. Sly PD, Boner AL, Bjorksten B, et al. Early identification of atopy in the prediction of persistent asthma in children. Lancet. 2008;372: 1100-1106.
40. Simpson A, Soderstrom L, Ahlstedt S, et al. IgE antibody quantification and the probability of wheeze in preschool children. J Allergy Clin Immunol. 2005;116:744-749.
41. Wickman M, Ahlstedt S, Lilja G, et al. Quantification of IgE antibodies simplifies the classification of allergic diseases in 4-year-old children. A report from the prospective birth cohort study - BAMSE. Pediatr Allergy Immunol. 2003;14:441-447.
42. Wickman M, Lilja G, Soderstrom L, et al. Quantitative analysis of IgE antibodies to food and inhalant allergens in 4-year-old children reflects their likelihood of allergic disease. Allergy. 2005;60:650-657.
43. Peters-Golden M, Henderson WR Jr. Leukotrienes. N Engl J Med. 2007;357:1841-1854.
44. Lam BK, Owen WF Jr, Austen KF, et al. The identification of a distinct export step following the biosynthesis of leukotriene C4 by human eosinophils. J Biol Chem. 1989;264:12885-12889.
45. Kawabe T, Chen ZS, Wada M, et al. Enhanced transport of anticancer agents and leukotriene C4 by the human canalicular multispecific organic anion transporter (cMOAT/MRP2). FEBS Lett. 1999;456:327-331.
46. Anderson ME, Allison RD, Meister A. Interconversion of leukotrienes catalyzed by purified gamma-glutamyl transpeptidase: concomitant formation of leukotriene D4 and gamma-glutamyl amino acids. Proc Natl Acad Sci U S A. 1982;79:1088-1091.
47. Lee CW, Lewis RA, Corey EJ, et al. Conversion of leukotriene D4 to leukotriene E4 by a dipeptidase released from the specific granule of human polymorphonuclear leucocytes. Immunology. 1983;48:27-35.
48. Drazen JM, Austen KF. Leukotrienes and airway responses. Am Rev Respir Dis. 1987;136:985-998.
49. Salvi SS, Krishna MT, Sampson AP, et al. The anti-inflammatory effects of leukotriene-modifying drugs and their use in asthma. Chest. 2001;119:1533-1546.
50. Dahlen SE, Kumlin M, Bjorck T, et al. Airway smooth muscle and disease workshop: leukotrienes and related eicosanoids. Am Rev Respir Dis. 1987;136:S24-S28.
51. Sala A, Voelkel N, Maclouf J, et al. Leukotriene E4 elimination and metabolism in normal human subjects. J Biol Chem. 1990;265:21771-21778.
52. Maltby NH, Taylor GW, Ritter JM, et al. Leukotriene C4 elimination and metabolism in man. J Allergy Clin Immunol. 1990;85:3-9.
53. Rabinovitch N. Urinary leukotriene E4. Immunol Allergy Clin North Am. 2007;27:651-664.
54. Mougey E, Lang J, Allayee H, et al. ALOX5 Polymorphism Associates with Increased Leukotriene Production and Reduced Lung Function and Asthma Control in Children with Poorly Controlled Asthma. Clin Exp Allergy. 2013. Accepted manuscript online: December 22, 2012.
55. Smith CM, Hawksworth RJ, Thien FC, et al. Urinary leukotriene E4 in bronchial asthma. Eur Respir J. 1992;5:693-699.
56. Jennings JE, Ramkumar T, Mao J, et al. Elevated urinary leukotriene E4 levels are associated with hospitalization for pain in children with sickle cell disease. Am J Hematol. 2008;83:640-643.
57. Field JJ, Krings J, White NL, et al. Urinary cysteinyl leukotriene E(4) is associated with increased risk for pain and acute chest syndrome in adults with sickle cell disease. Am J Hematol. 2009;84:158-160.
58. Kurokawa K, Tanaka H, Tanaka S, et al. Circadian characteristics of urinary leukotriene E(4) in healthy subjects and nocturnal asthmatic patients. Chest. 2001;120:1822-1828.
59. Bellia V, Bonanno A, Cibella F, et al. Urinary leukotriene E4 in the assessment of nocturnal asthma. J Allergy Clin Immunol. 1996; 97:735-741.
60. Szefler SJ, Phillips BR, Martinez FD, et al. Characterization of within-subject responses to fluticasone and montelukast in childhood asthma. J Allergy Clin Immunol. 2005;115:233-242.
61. Rabinovitch N, Graber NJ, Chinchilli VM, et al. Urinary leukotriene E4/exhaled nitric oxide ratio and montelukast response in childhood asthma. J Allergy Clin Immunol. 2010;126:545-551 e541-e544.
62. Cai C, Yang J, Hu S, et al. Relationship between urinary cysteinyl leukotriene E4 levels and clinical response to antileukotriene treatment in patients with asthma. Lung. 2007;185:105-112.
63. Tse SM, Tantisira K, Weiss ST. The pharmacogenetics and pharmacogenomics of asthma therapy. Pharmacogenomics J. 2011;11:383-392.
64. Kanaoka Y, Boyce JA. Cysteinyl leukotrienes and their receptors: cellular distribution and function in immune and inflammatory responses. J Immunol. 2004;173:1503-1510.
65. In KH, Asano K, Beier D, et al. Naturally occurring mutations in the human 5-lipoxygenase gene promoter that modify transcription factor binding and reporter gene transcription. J Clin Invest. 1997;99:1130-1137.
66. Drazen JM, Israel E, O'Byrne PM. Treatment of asthma with drugs modifying the leukotriene pathway. N Engl J Med. 1999;340:197-206.
67. Telleria JJ, Blanco-Quiros A, Varillas D, et al. ALOX5 promoter genotype and response to montelukast in moderate persistent asthma. Respir Med. 2008;102:857-861.
68. Lima JJ, Zhang S, Grant A, et al. Influence of leukotriene pathway polymorphisms on response to montelukast in asthma. Am J Respir Crit Care Med. 2006;173:379-385.
69. Klotsman M, York TP, Pillai SG, et al. Pharmacogenetics of the 5-lipoxygenase biosynthetic pathway and variable clinical response to montelukast. Pharmacogenet Genomics. 2007;17:189-196.
70. Mougey EB, Feng H, Castro M, et al. Absorption of montelukast is transporter mediated: a common variant of OATP2B1 is associated with reduced plasma concentrations and poor response. Pharmacogenet Genomics. 2009;19:129-138.
71. Lima JJ, Zhang S, Grant A, et al. Influence of leukotriene pathway polymorphisms on response to montelukast in asthma. Am J Respir Crit Care Med. 2006;173:379-385.
72. Tantisira KG, Lima J, Sylvia J, et al. 5-lipoxygenase pharmacogenetics in asthma: overlap with Cys-leukotriene receptor antagonist loci. Pharmacogenet Genomics. 2009;19:244-247.
73. Klotsman M, York TP, Pillai SG, et al. Pharmacogenetics of the 5-lipoxygenase biosynthetic pathway and variable clinical response to montelukast. Pharmacogenet Genomics. 2007;17:189-196.
74. Sampson AP, Siddiqui S, Buchanan D, et al. Variant LTC(4) synthase allele modifies cysteinyl leukotriene synthesis in eosinophils and predicts clinical response to zafirlukast. Thorax. 2000;55 Suppl 2: S28-S31.
75. Asano K, Shiomi T, Hasegawa N, et al. Leukotriene C4 synthase gene A(-444)C polymorphism and clinical response to a CYS-LT(1) antagonist, pranlukast, in Japanese patients with moderate asthma. Pharmacogenetics. 2002;12:565-570.
76. Whelan GJ, Blake K, Kissoon N, et al. Effect of montelukast on time-course of exhaled nitric oxide in asthma: influence of LTC4 synthase A(-444)C polymorphism. Pediatr Pulmonol. 2003;36:413-420.
77. Kotani H, Kishi R, Mouri A, et al. Influence of leukotriene pathway polymorphisms on clinical responses to montelukast in Japanese patients with asthma. J Clin Pharm Ther. 2012;37:112-116.
78. Filppula AM, Laitila J, Neuvonen PJ, et al. Reevaluation of the microsomal metabolism of montelukast: major contribution by CYP2C8 at clinically relevant concentrations. Drug Metab Dispos. 2011;39:904-911.
79. Mougey EB, Feng H, Castro M, et al. Absorption of montelukast is transporter mediated: a common variant of OATP2B1 is associated with reduced plasma concentrations and poor response. Pharmacogenet Genomics. 2009;19:129-138.
80. Ahmadzai H, Huang S, Hettiarachchi R, et al. Exhaled breath condensate: a comprehensive update. Clin Chem Lab Med. 2013:1-19.
81. Rosias PP, Robroeks CM, Niemarkt HJ, et al. Breath condenser coatings affect measurement of biomarkers in exhaled breath condensate. Eur Respir J. 2006;28:1036-1041.
82. Montuschi P. Analysis of exhaled breath condensate in respiratory medicine: methodological aspects and potential clinical applications. Ther Adv Respir Dis. 2007;1:5-23.
83. Soyer OU, Dizdar EA, Keskin O, et al. Comparison of two methods for exhaled breath condensate collection. Allergy. 2006;61:1016-1018.
84. Czebe K, Barta I, Antus B, et al. Influence of condensing equipment and temperature on exhaled breath condensate pH, total protein and leukotriene concentrations. Respir Med. 2008;102:720-725.
85. CDC. Vital signs: current cigarette smoking among adults aged/=18 years - United States, 2005-2010. MMWR Morb Mortal Wkly Rep. 2011;60:1207-1212.
86. Moritsugu KP. The 2006 Report of the Surgeon General: the health consequences of involuntary exposure to tobacco smoke. Am J Prev Med. 2007;32:542-543.
87. CDC. Vital Signs: nonsmokers' exposure to secondhand smoke - United States, 1999-2008. MMWR Morb Mortal Wkly Rep. 2010;59: 1141-1146.
88. Burke H, Leonardi-Bee J, Hashim A, et al. Prenatal and passive smoke exposure and incidence of asthma and wheeze: systematic review and meta-analysis. Pediatrics. 2012;129:735-744.
89. United States. Public Health Service. Office of the Surgeon General. The health consequences of involuntary exposure to tobacco smoke: a report of the Surgeon General. Rockville, MD: US Dept of Health and Human Services, Public Health Service, Office of the Surgeon General, 2006.
90. DiFranza JR, Aligne CA, Weitzman M. Prenatal and postnatal environmental tobacco smoke exposure and children's health. Pediatrics. 2004;113:1007-1015.
91. Evans D, Levison MJ, Feldman CH, et al. The impact of passive smoking on emergency room visits of urban children with asthma. Am Rev Respir Dis. 1987;135:567-572.
92. Murray AB, Morrison BJ. Passive smoking and the seasonal difference of severity of asthma in children. Chest. 1988;94:701-708.
93. Weitzman M, Gortmaker S, Walker DK, et al. Maternal smoking and childhood asthma. Pediatrics. 1990;85:505-511.
94. Chilmonczyk BA, Salmun LM, Megathlin KN, et al. Association between exposure to environmental tobacco smoke and exacerbations of asthma in children. N Engl J Med. 1993;328:1665-1669.
95. Lodrup Carlsen KC, Carlsen KH. Effects of maternal and early tobacco exposure on the development of asthma and airway hyperreactivity. Curr Opin Allergy Clin Immunol. 2001;1:139-143.
96. Goksor E, Amark M, Alm B, et al. The impact of pre-and post-natal smoke exposure on future asthma and bronchial hyper-responsiveness. Acta Paediatr. 2007;96:1030-1035.
97. Cook DG, Strachan DP. Health effects of passive smoking. 3. Parental smoking and prevalence of respiratory symptoms and asthma in school age children. Thorax. 1997;52:1081-1094.
98. Mannino DM, Moorman JE, Kingsley B, et al. Health effects related to environmental tobacco smoke exposure in children in the United States: data from the Third National Health and Nutrition Examination Survey. Arch Pediatr Adolesc Med. 2001;155:36-41.
99. Murray AB, Morrison BJ. The effect of cigarette smoke from the mother on bronchial responsiveness and severity of symptoms in children with asthma. J Allergy Clin Immunol. 1986;77:575-581.
100. Murray AB, Morrison BJ. Passive smoking by asthmatics: its greater effect on boys than on girls and on older than on younger children. Pediatrics. 1989;84:451-459.
101. O'Connor GT, Weiss ST, Tager IB, et al. The effect of passive smoking on pulmonary function and nonspecific bronchial responsiveness in a population-based sample of children and young adults. Am Rev Respir Dis. 1987;135:800-804.
102. Martinez FD, Antognoni G, Macri F, et al. Parental smoking enhances bronchial responsiveness in nine-year-old children. Am Rev Respir Dis. 1988;138:518-523.
103. Marquette CH, Saulnier F, Leroy O, et al. Long-term prognosis of near-fatal asthma. A 6-year follow-up study of 145 asthmatic patients who underwent mechanical ventilation for a near-fatal attack of asthma. Am Rev Respir Dis. 1992;146:76-81.
104. Osborne ML, Pedula KL, O'Hollaren M, et al. Assessing future need for acute care in adult asthmatics: the Profile of Asthma Risk Study: a prospective health maintenance organization-based study. Chest. 2007;132:1151-1161.
105. Quest. Cotinine, Urine, 2013.
106. Mayo Clinic ML. Nicotine and Metabolites, Urine, 2013.
107. Benowitz NL. Cotinine as a biomarker of environmental tobacco smoke exposure. Epidemiol Rev. 1996;18:188-204.
108. Goniewicz ML, Havel CM, Peng MW, et al. Elimination kinetics of the tobacco-specific biomarker and lung carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol. Cancer Epidemiol Biomarkers Prev. 2009;18:3421-3425.
109. Tantisira KG, Lasky-Su J, Harada M, et al. Genomewide association between GLCCI1 and response to glucocorticoid therapy in asthma. N Engl J Med. 2011;365:1173-1183.
110. Yoshikawa T, Shoji S, Fujii T, et al. Severity of exercise-induced bronchoconstriction is related to airway eosinophilic inflammation in patients with asthma. Eur Respir J. 1998;12:879-884.
111. Reiss TF, Hill JB, Harman E, et al. Increased urinary excretion of LTE4 after exercise and attenuation of exercise-induced bronchospasm by montelukast, a cysteinyl leukotriene receptor antagonist. Thorax. 1997;52:1030-1035.
112. De Gouw HW, Marshall-Partridge SJ, Van Der Veen H, et al. Role of nitric oxide in the airway response to exercise in healthy and asthmatic subjects. J Appl Physiol. 2001;90:586-592.
113. Sleiman PM, Flory J, Imielinski M, et al. Variants of DENND1B associated with asthma in children. N Engl J Med. 2010;362:36-44.
114. Ober C, Tan Z, Sun Y, et al. Effect of variation in CHI3L1 on serum YKL-40 level, risk of asthma, and lung function. N Engl J Med. 2008;358:1682-1691.
115. Gudbjartsson DF, Bjornsdottir US, Halapi E, et al. Sequence variants affecting eosinophil numbers associate with asthma and myocardial infarction. Nat Genet. 2009;41:342-347.
116. Moffatt MF, Gut IG, Demenais F, et al. A large-scale, consortium-based genomewide association study of asthma. N Engl J Med. 2010;363:1211-1221.
117. Allen M, Heinzmann A, Noguchi E, et al. Positional cloning of a novel gene influencing asthma from chromosome 2q14. Nat Genet. 2003;35:258-263.
118. Mathias RA, Grant AV, Rafaels N, et al. A genome-wide association study on African-ancestry populations for asthma. J Allergy Clin Immunol. 2010;125:336-346 e334.
119. Himes BE, Hunninghake GM, Baurley JW, et al. Genome-wide association analysis identifies PDE4D as an asthma-susceptibility gene. Am J Hum Genet. 2009;84:581-593.
120. Basehore MJ, Howard TD, Lange LA, et al. A comprehensive evaluation of IL4 variants in ethnically diverse populations: association of total serum IgE levels and asthma in white subjects. J Allergy Clin Immunol. 2004;114:80-87.
121. Koppelman GH, Meyers DA, Howard TD, et al. Identification of PCDH1 as a novel susceptibility gene for bronchial hyperresponsiveness. Am J Respir Crit Care Med. 2009;180:929-935.
122. Li X, Howard TD, Zheng SL, et al. Genome-wide association study of asthma identifies RAD50-IL13 and HLA-DR/DQ regions. J Allergy Clin Immunol. 2010;125:328-335 e311.
123. Laitinen T, Daly MJ, Rioux JD, et al. A susceptibility locus for asthma-related traits on chromosome 7 revealed by genome-wide scan in a founder population. Nat Genet. 2001;28:87-91.
124. Leaves NI, Bhattacharyya S, Wiltshire S, et al. A detailed genetic map of the chromosome 7 bronchial hyper-responsiveness locus. Eur J Hum Genet. 2002;10:177-182.
125. Van Eerdewegh P, Little RD, Dupuis J, et al. Association of the ADAM33 gene with asthma and bronchial hyperresponsiveness. Nature. 2002;418:426-430.
126. Himes BE, Jiang X, Hu R, et al. Genome-wide association analysis in asthma subjects identifies SPATS2L as a novel bronchodilator response gene. PLoS Genet. 2012;8:e1002824.
127. Israel E, Drazen JM, Liggett SB, et al. The effect of polymorphisms of the beta(2)-adrenergic receptor on the response to regular use of albuterol in asthma. Am J Respir Crit Care Med. 2000;162:75-80.
128. Lima JJ, Thomason DB, Mohamed MH, et al. Impact of genetic polymorphisms of the beta2-adrenergic receptor on albuterol bronchodilator pharmacodynamics. Clin Pharmacol Ther. 1999;65:519-525.
129. Martinez FD, Graves PE, Baldini M, et al. Association between genetic polymorphisms of the beta2-adrenoceptor and response to albuterol in children with and without a history of wheezing. J Clin Invest. 1997;100:3184-3188.
130. Burchard EG, Silverman EK, Rosenwasser LJ, et al. Association between a sequence variant in the IL-4 gene promoter and FEV(1) in asthma. Am J Respir Crit Care Med. 1999;160:919-922.
131. Choudhry S, Avila PC, Nazario S, et al. CD14 tobacco gene-environment interaction modifies asthma severity and immunoglobulin E levels in Latinos with asthma. Am J Respir Crit Care Med. 2005;172: 173-182.
132. Martin AC, Laing IA, Khoo SK, et al. Acute asthma in children: Relationships among CD14 and CC16 genotypes, plasma levels, and severity. Am J Respir Crit Care Med. 2006;173:617-622.
133. Tantisira KG, Damask A, Szefler SJ, et al. Genome-wide association identifies the T gene as a novel asthma pharmacogenetic locus. Am J Respir Crit Care Med. 2012;185:1286-1291.
134. Drazen JM, Yandava CN, Dube L, et al. Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment. Nat Genet. 1999;22:168-170.
135. Mougey E, Lang JE, Allayee H, et al. ALOX5 Polymorphism associates with increased leukotriene production and reduced lung function and asthma control in children with poorly controlled asthma. Clin Exp Allergy. 2012;43:512-520.
136. Tantisira KG, Lake S, Silverman ES, et al. Corticosteroid pharmacogenetics: association of sequence variants in CRHR1 with improved lung function in asthmatics treated with inhaled corticosteroids. Hum Mol Genet. 2004;13:1353-1359.
137. Bisgaard H, Bonnelykke K, Sleiman PM, et al. Chromosome 17q21 gene variants are associated with asthma and exacerbations but not atopy in early childhood. Am J Respir Crit Care Med. 2009;179: 179-185.
138. Tavendale R, Macgregor DF, Mukhopadhyay S, et al. A polymorphism controlling ORMDL3 expression is associated with asthma that is poorly controlled by current medications. J Allergy Clin Immunol. 2008;121:860-863.
139. Foley SC, Mogas AK, Olivenstein R, et al. Increased expression of ADAM33 and ADAM8 with disease progression in asthma. J Allergy Clin Immunol. 2007;119:863-871.
140. Vijverberg SJ, Koster ES, Koenderman L, et al. Exhaled NO is a poor marker of asthma control in children with a reported use of asthma medication: a pharmacy-based study. Pediatr Allergy Immunol. 2012;23:529-536.
141. Yavuz ST, Civelek E, Sahiner UM, et al. Identifying uncontrolled asthma in children with the childhood asthma control test or exhaled nitric oxide measurement. Ann Allergy Asthma Immunol. 2012;109: 36-40.
142. Telleria JJ, Blanco-Quiros A, Varillas D, et al. ALOX5 promoter genotype and response to montelukast in moderate persistent asthma. Respir Med. 2008;102:857-861.
143. Jones IA, St Helen G, Meyers MJ, et al. Biomarkers of secondhand smoke exposure in automobiles. Tob Control. 2013. [Epub ahead of print].